Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
April 17, 2020

Inovio gets grant to partner with IVI and KNIH for Covid-19 vaccine

Inovio Pharmaceuticals has received $6.9m in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to collaborate with the International Vaccine Institute (IVI) and the Korea National Institute of Health (KNIH) for a Covid-19 vaccine trial.

The alliance is for a Phase I/II trial of Inovio’s vaccine candidate, INO-4800, in South Korea. IVI will perform the trial in parallel with Inovio’s Phase I trial conducted in the US.

Read the full article here

Related Companies

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU